File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clozapine use in schizophrenia: Findings of the Research on Asia Psychotropic Prescription (REAP) studies from 2001 to 2009

TitleClozapine use in schizophrenia: Findings of the Research on Asia Psychotropic Prescription (REAP) studies from 2001 to 2009
Authors
Issue Date2011
PublisherInforma Healthcare. The Journal's web site is located at http://informahealthcare.com/anp
Citation
Australian And New Zealand Journal Of Psychiatry, 2011, v. 45 n. 11, p. 968-975 How to Cite?
AbstractObjective: Optimizing treatment and outcomes for people with schizophrenia requires understanding of how evidence-based treatments are utilized. Clozapine is the most effective antipsychotic drug for treatment-refractory schizophrenia, but few studies have investigated trends and patterns of its use over time internationally. This study examined the prescription patterns of clozapine and its demographic and clinical correlates in Asia from 2001 to 2009. Method: Clozapine prescriptions were collected in a sample of 6761 hospitalized schizophrenia patients in nine Asian countries and regions using a standardized protocol and data collection procedure. Results: Overall, the proportion of patients receiving clozapine prescriptions was stable across the three surveys from 2001 to 2009, ranging from 14.5% to 15.9%. However, the rates and patterns observed within different regions and countries at each survey differed considerably. Clozapine use decreased significantly over time in China, while it increased in Korea and Singapore. Multiple logistic regression analysis revealed that patients taking clozapine were significantly younger, had a higher dose of antipsychotic drugs in chlorpromazine equivalents, were more likely to be female, had fewer extrapyramidal symptoms, and had more negative symptoms, admissions and weight gain in the past month than those not receiving clozapine. Conclusion: The variability in overall rates and changes in prescription rates over time in these samples suggest that factors other than psychopharmacological principles play an important role in determining the use of clozapine in schizophrenia in Asia. © 2011 The Royal Australian and New Zealand College of Psychiatrists.
Persistent Identifierhttp://hdl.handle.net/10722/171974
ISSN
2015 Impact Factor: 3.536
2015 SCImago Journal Rankings: 1.269
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorXiang, YTen_US
dc.contributor.authorWang, CYen_US
dc.contributor.authorSi, TMen_US
dc.contributor.authorLee, EHMen_US
dc.contributor.authorHe, YLen_US
dc.contributor.authorUngvari, GSen_US
dc.contributor.authorChiu, HFKen_US
dc.contributor.authorShinfuku, Nen_US
dc.contributor.authorYang, SYen_US
dc.contributor.authorChong, MYen_US
dc.contributor.authorKua, EHen_US
dc.contributor.authorFujii, Sen_US
dc.contributor.authorSim, Ken_US
dc.contributor.authorYong, MKHen_US
dc.contributor.authorTrivedi, JKen_US
dc.contributor.authorChung, EKen_US
dc.contributor.authorUdomratn, Pen_US
dc.contributor.authorChee, KYen_US
dc.contributor.authorSartorius, Nen_US
dc.contributor.authorDixon, LBen_US
dc.contributor.authorKreyenbuhl, JAen_US
dc.contributor.authorTan, CHen_US
dc.date.accessioned2012-10-30T06:19:04Z-
dc.date.available2012-10-30T06:19:04Z-
dc.date.issued2011en_US
dc.identifier.citationAustralian And New Zealand Journal Of Psychiatry, 2011, v. 45 n. 11, p. 968-975en_US
dc.identifier.issn0004-8674en_US
dc.identifier.urihttp://hdl.handle.net/10722/171974-
dc.description.abstractObjective: Optimizing treatment and outcomes for people with schizophrenia requires understanding of how evidence-based treatments are utilized. Clozapine is the most effective antipsychotic drug for treatment-refractory schizophrenia, but few studies have investigated trends and patterns of its use over time internationally. This study examined the prescription patterns of clozapine and its demographic and clinical correlates in Asia from 2001 to 2009. Method: Clozapine prescriptions were collected in a sample of 6761 hospitalized schizophrenia patients in nine Asian countries and regions using a standardized protocol and data collection procedure. Results: Overall, the proportion of patients receiving clozapine prescriptions was stable across the three surveys from 2001 to 2009, ranging from 14.5% to 15.9%. However, the rates and patterns observed within different regions and countries at each survey differed considerably. Clozapine use decreased significantly over time in China, while it increased in Korea and Singapore. Multiple logistic regression analysis revealed that patients taking clozapine were significantly younger, had a higher dose of antipsychotic drugs in chlorpromazine equivalents, were more likely to be female, had fewer extrapyramidal symptoms, and had more negative symptoms, admissions and weight gain in the past month than those not receiving clozapine. Conclusion: The variability in overall rates and changes in prescription rates over time in these samples suggest that factors other than psychopharmacological principles play an important role in determining the use of clozapine in schizophrenia in Asia. © 2011 The Royal Australian and New Zealand College of Psychiatrists.en_US
dc.languageengen_US
dc.publisherInforma Healthcare. The Journal's web site is located at http://informahealthcare.com/anpen_US
dc.relation.ispartofAustralian and New Zealand Journal of Psychiatryen_US
dc.subject.meshAdulten_US
dc.subject.meshAntipsychotic Agents - Adverse Effects - Therapeutic Useen_US
dc.subject.meshAsiaen_US
dc.subject.meshClozapine - Adverse Effects - Therapeutic Useen_US
dc.subject.meshDrug Resistance - Drug Effectsen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPhysician's Practice Patterns - Statistics & Numerical Data - Trendsen_US
dc.subject.meshSchizophrenia - Diagnosis - Drug Therapyen_US
dc.titleClozapine use in schizophrenia: Findings of the Research on Asia Psychotropic Prescription (REAP) studies from 2001 to 2009en_US
dc.typeArticleen_US
dc.identifier.emailLee, EHM:edwinlhm@hku.hken_US
dc.identifier.authorityLee, EHM=rp01575en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.3109/00048674.2011.607426en_US
dc.identifier.pmid21888603-
dc.identifier.scopuseid_2-s2.0-80555145990en_US
dc.identifier.hkuros206284-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-80555145990&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume45en_US
dc.identifier.issue11en_US
dc.identifier.spage968en_US
dc.identifier.epage975en_US
dc.identifier.isiWOS:000296457400010-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridXiang, YT=35241398400en_US
dc.identifier.scopusauthoridWang, CY=47961486300en_US
dc.identifier.scopusauthoridSi, TM=6701400479en_US
dc.identifier.scopusauthoridLee, EHM=7406967099en_US
dc.identifier.scopusauthoridHe, YL=35313337300en_US
dc.identifier.scopusauthoridUngvari, GS=7006092063en_US
dc.identifier.scopusauthoridChiu, HFK=24447976700en_US
dc.identifier.scopusauthoridShinfuku, N=7003855366en_US
dc.identifier.scopusauthoridYang, SY=25958514300en_US
dc.identifier.scopusauthoridChong, MY=7102632108en_US
dc.identifier.scopusauthoridKua, EH=7006748699en_US
dc.identifier.scopusauthoridFujii, S=7401814463en_US
dc.identifier.scopusauthoridSim, K=8513485500en_US
dc.identifier.scopusauthoridYong, MKH=47161681100en_US
dc.identifier.scopusauthoridTrivedi, JK=7005836490en_US
dc.identifier.scopusauthoridChung, EK=7202734618en_US
dc.identifier.scopusauthoridUdomratn, P=6602459819en_US
dc.identifier.scopusauthoridChee, KY=36100061600en_US
dc.identifier.scopusauthoridSartorius, N=7102159482en_US
dc.identifier.scopusauthoridDixon, LB=35372257700en_US
dc.identifier.scopusauthoridKreyenbuhl, JA=6602795669en_US
dc.identifier.scopusauthoridTan, CH=7402817882en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats